Dr. Vincent Anthony Restivo, MD

Dr. Restivo practices at Oakwood Surgery Center in Round Rock, Texas.

Dr. Restivo's NPI, 1811967821, was assigned on January 23, 2006. Dr. Restivo graduated from McGovern Medical School in 1997. Dr. Restivo holds Texas license K6970.

Dr. Restivo's primary practice is Oakwood Surgery Center, at 16030 Park Valley, Ste 100, Round Rock, TX 78681. The practice phone is (512) 246-8777.

Dr. Restivo's primary practice is Oakwood Surgery Center in Round Rock, Texas. Dmand AI also links Dr. Restivo to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Restivo practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Restivo's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Restivo is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Restivo is licensed in Texas.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Restivo treats.

CMS data shows 2,467 Medicare services from Dr. Restivo across 18 procedure codes in 2024, for 860 Medicare patients. Medicare paid $287,711 for them.

CMS counts 860 Medicare patients who saw Dr. Restivo in 2024. The largest group is 65 to 74, with 384 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Restivo's median patient age at 73, with 57% women.

In 2024, Dr. Restivo wrote 1,221 Medicare Part D claims for 362 patients. 50% of them were for generic drugs. CMS names the drug for 1,144 of them, across 17 drugs with 11 or more claims each, at $354,196 in total drug cost. In 2023, CMS named 1,120 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Restivo for performance year 2024, reported as part of a group. Dr. Restivo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 544 procedures of cataract surgery by Dr. Restivo, more than 96% of the clinicians it reports for that procedure.

Dmand AI links Dr. Restivo to 3 clinical trials. Conditions studied include Cataract, Lens Diseases and Hyperemia. Bausch & Lomb Incorporated sponsors the most, 2. Open Payments lists research payments to Dr. Restivo that name 2 trials.

CMS Open Payments shows 275 general payments to Dr. Restivo from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 78% of the total. Valeant Pharmaceuticals International paid the most, $2,305. It also lists 8 research payments totaling $151,409 from 2018 to 2020, naming 2 clinical trials.

Dmand AI lists 2 awards for Dr. Restivo, most recently CMS Stage 1 2012 in 2012.

Dr. Restivo graduated from McGovern Medical School in 1997. Dr. Restivo is a member of AAO.

Dr. Restivo is in network with 22 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.